 |
29 Products |  |
56 Diseases | | 29 Products |
|
154 Trials |  |
7480 News |  |
| «12...87888990919293949596979899» |
- ||||| Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment change, Combination therapy: Long-term Treatment Study of Certolizumab Pegol (CDP870) as Add-on Medication to Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients (clinicaltrials.gov) - Jun 25, 2013
P3, N=285, Completed, Sponsor: Astellas Pharma Inc
N=222 --> 285
- ||||| Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment change: Long-term Treatment Study of Certolizumab Pegol Without Coadministration of Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients (clinicaltrials.gov) - Jun 25, 2013
P3, N=208, Completed, Sponsor: Astellas Pharma Inc
N=222 --> 285 N=130 --> 208
- ||||||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion, Combination therapy: Long-term Treatment Study of Certolizumab Pegol (CDP870) as Add-on Medication to Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients (clinicaltrials.gov) - Jun 25, 2013
P3, N=285, Completed, Sponsor: Astellas Pharma Inc
N=130 --> 208 Active, not recruiting --> Completed
- ||||||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion: Long-term Treatment Study of Certolizumab Pegol Without Coadministration of Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients (clinicaltrials.gov) - Jun 25, 2013
P3, N=208, Completed, Sponsor: Astellas Pharma Inc
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Cervidil (dinoprostone) / Ferring
Trial initiation date: Efficacy of Induction of Labor on Term Using a Double Balloon Catheter Compared to Dinoprostone Vaginal-insert (clinicaltrials.gov) - Jun 24, 2013
P4, N=253, Not yet recruiting, Sponsor: Medical University of Graz
Active, not recruiting --> Completed Initiation date: Jan 2013 --> Aug 2013
- Firmagon (degarelix) / Astellas, Ferring
Enrollment open: Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer (clinicaltrials.gov) - Jun 20, 2013
P=N/A, N=20, Recruiting, Sponsor: University of Washington
Initiation date: Jan 2013 --> Aug 2013 Not yet recruiting --> Recruiting
- ||| Firmagon (degarelix) / Astellas, Ferring
Enrollment open: Impact of the Geographical FACTor on the Prostate Cancer Stage at Hormonal Therapy Initiation (clinicaltrials.gov) - Jun 3, 2013
P=N/A, N=300, Recruiting, Sponsor: Ferring Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion, MRI: MARVELOUS: Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Jun 3, 2013
P3, N=41, Completed, Sponsor: UCB, Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Cervidil (dinoprostone) / Ferring
New P4 trial: Success rate of initiation of birth process at term by inserting a balloon into the cervix compared by inserting a vaginal delivery system (dinoprostone). Erfolgsrate bei Einleitung des Geburtsvorganges am Termin durch Einlegen eines Ballons in den Muttermund im Vergleich durch Einlegen eines vaginalen Freisetzungssystem (Dinoproston). (EUDRACT) - May 28, 2013
P4, N=253, Ongoing, Sponsor: Medizinische Universit
- || Cimzia (certolizumab pegol) / Astellas, UCB
New P3 trial: PreCePRA: Prediction of Response to Certolizumab Pegol Treatment by Functional MRI of the Brain (clinicaltrials.gov) - May 27, 2013
P3, N=156, Recruiting, Sponsor: University of Erlangen-N
- ||| Firmagon (degarelix) / Astellas, Ferring
Metastases: Effectiveness and Safety of Firmagon (clinicaltrials.gov) - May 21, 2013
P=N/A, N=200, Recruiting, Sponsor: Ferring Pharmaceuticals
- Cervidil (dinoprostone) / Ferring
Enrollment open: Foley Catheter Versus Dinoprostone Vaginal Insert for Induction of Labor in Parous Women at Term: A Randomized Trial (clinicaltrials.gov) - May 21, 2013
P=N/A, N=154, Recruiting, Sponsor: Seoul National University Hospital
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Sufenta (sufentanil) / Akorn
Clinical: Programmed Intermittent Epidural Bolus Versus Continuous Epidural Infusion for Termination of Pregnancy Analgesia (clinicaltrials.gov) - May 20, 2013
P=N/A, N=98, Recruiting, Sponsor: IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
- New P4 trial: Evaluation of a protocol for the reduction of doses in patients with rheumatoid arthritis (RA) in clinical remission in treatment with biological therapies Evaluaci (EUDRACT) - May 15, 2013
P4, N=28, Ongoing, Sponsor: FRANCISCO J. BLANCO GARC
- | Firmagon (degarelix) / Astellas, Ferring
New P2 trial: HyBraFi: Toxicity Comparison Between Hypofractionated Radiotherapy With HDR Brachytherapy Boost Versus Standard Treatment (clinicaltrials.gov) - May 8, 2013
P2, N=30, Active, not recruiting, Sponsor: Centre Hospitalier Universitaire de Qu
- || Cervidil (dinoprostone) / Ferring
Enrollment closed: Foley Catheter Versus Cervidil for Induction of Labor at Term (clinicaltrials.gov) - May 8, 2013
P=N/A, N=330, Active, not recruiting, Sponsor: Obstetrix Medical Group
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed, HEOR: RA-PROACTIVE: Long Term Effects of an Early Response to Certolizumab Pegol (CZP, Cimzia (clinicaltrials.gov) - Apr 29, 2013
P=N/A, N=145, Active, not recruiting, Sponsor: UCB, Inc.
Recruiting --> Active, not recruiting Enrolling by invitation --> Active, not recruiting
- || Firmagon (degarelix) / Astellas, Ferring
Enrollment closed, Metastases: A Safety Study in Patients With Advanced Prostate Cancer Treated With FIRMAGON (clinicaltrials.gov) - Apr 21, 2013
P=N/A, N=1500, Active, not recruiting, Sponsor: Ferring Pharmaceuticals
Enrolling by invitation --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| Rekovelle (follitropin delta) / Ferring
Trial completion: A Dose-response Trial Using rFSH FE 999049 in Women Undergoing IVF/ICSI Treatment (clinicaltrials.gov) - Apr 18, 2013
P2, N=265, Completed, Sponsor: Ferring Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Menopur (menotropin) / Ferring
Enrollment change: Gonadotrophin Dosage Using a Threshold Nomogram for Ovulation Induction in WHO Group II Anovulatory Infertility (clinicaltrials.gov) - Apr 17, 2013
P4, N=75, Completed, Sponsor: Rigshospitalet, Denmark
Active, not recruiting --> Completed N=60 --> 75
- Menopur (menotropin) / Ferring
Trial completion: Gonadotrophin Dosage Using a Threshold Nomogram for Ovulation Induction in WHO Group II Anovulatory Infertility (clinicaltrials.gov) - Apr 17, 2013
P4, N=75, Completed, Sponsor: Rigshospitalet, Denmark
N=60 --> 75 Not yet recruiting --> Completed
- ||| Goofice (elobixibat) / Eisai, Mochida, Ipsen
New P3 trial: Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation (clinicaltrials.gov) - Apr 14, 2013
P3, N=840, Suspended, Sponsor: Ferring Pharmaceuticals
- ||||||| Testavan (transdermal testosterone gel 2%) / Ferring
Trial completion: A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel (clinicaltrials.gov) - Apr 9, 2013
P3, N=180, Completed, Sponsor: Ferring Pharmaceuticals
Not yet recruiting --> Completed Active, not recruiting --> Completed
- ||| Goofice (elobixibat) / Eisai, Mochida, Ipsen
New P3 trial: 26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation (clinicaltrials.gov) - Apr 7, 2013
P3, N=840, Suspended, Sponsor: Ferring Pharmaceuticals
- Euflexxa (hyaluronic acid) / Ferring
Enrollment change: Three Injections of EUFLEXXA (Sodium Hyaluronate) for Treatment of Chronic Shoulder Pain Associated With Osteoarthritis (OA) (clinicaltrials.gov) - Mar 26, 2013
P=N/A, N=32, Completed, Sponsor: Georgia Institute for Clinical Research, LLC
Active, not recruiting --> Completed N=25 --> 32
- ||||| Merional (menotropin) / IBSA Institute Biochemical SA
Enrollment closed: Safety and Efficacy Study in in Vitro Fertilisation (IVF) Patients (clinicaltrials.gov) - Mar 26, 2013
P3, N=272, Active, not recruiting, Sponsor: IBSA Institut Biochimique SA
N=25 --> 32 Recruiting --> Active, not recruiting
- |||||||||| Cimzia (certolizumab pegol) / Astellas, UCB
New P3 trial: Cimzia Versus Cimzia Plus Azathioprine in the Treatment of Active Crohn's Disease (clinicaltrials.gov) - Mar 24, 2013
P3, N=65, Not yet recruiting, Sponsor: Gastroenterology Research of America
- | Eligard (leuprolide acetate) / Tolmar, Sanofi, Recordati, Firmagon (degarelix) / Astellas, Ferring
Trial completion: Initiation of Androgen Deprivation Therapy for Prostate Cancer Using Degarelix Followed by Leuprolide (clinicaltrials.gov) - Mar 14, 2013
P=N/A, N=50, Completed, Sponsor: Urology of Virginia
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| Euflexxa (hyaluronic acid) / Ferring
New P4 trial: Effectiveness Trial for Evaluating IAHA for PFPS (clinicaltrials.gov) - Mar 12, 2013
P4, N=68, Recruiting, Sponsor: New York University School of Medicine
- Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion, Combination therapy, Patient reported outcomes: PICS: The Effect of Certolizumab Pegol on MRI Synovitis and Bone Edema in Rheumatoid Arthritis Patients (clinicaltrials.gov) - Mar 6, 2013
P3, N=20, Completed, Sponsor: Oklahoma Medical Research Foundation
Active, not recruiting --> Completed Not yet recruiting --> Completed
- | Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment open: Cimzia Versus Mesalamine for Crohn's Recurrence (clinicaltrials.gov) - Feb 25, 2013
P4, N=24, Recruiting, Sponsor: Milton S. Hershey Medical Center
Not yet recruiting --> Completed Not yet recruiting --> Recruiting
- | Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment change: Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol (clinicaltrials.gov) - Feb 11, 2013
P2, N=16, Active, not recruiting, Sponsor: UCB, Inc.
Not yet recruiting --> Recruiting N=100 --> 16
- ||||| Yonsa (abiraterone acetate) / Sun Pharma
New P2 trial: NCI-2018-01856: Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer (clinicaltrials.gov) - Feb 5, 2013
P2, N=200, Recruiting, Sponsor: M.D. Anderson Cancer Center
- | Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment open: SCINTRA: Scintigraphic Detection of the Biodistribution of Tumor Necrosis Factor With a Radiolabeled Anti-TNF? in Patients With Active Rheumatoid Arthritis and Active Axial and Peripheral Spondyloarthritis (clinicaltrials.gov) - Jan 31, 2013
P3, N=20, Recruiting, Sponsor: University Hospital, Ghent
N=100 --> 16 Not yet recruiting --> Recruiting
- Zomacton (somatropin) / Ferring
Trial withdrawal: Surveillance of Treatment of Children With Growth Hormone Deficiency With Zomacton (clinicaltrials.gov) - Jan 30, 2013
P=N/A, N=0, Withdrawn, Sponsor: Ferring Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Withdrawn
- Zomacton (somatropin) / Ferring
Enrollment change: Surveillance of Treatment of Children With Growth Hormone Deficiency With Zomacton (clinicaltrials.gov) - Jan 30, 2013
P=N/A, N=0, Withdrawn, Sponsor: Ferring Pharmaceuticals
Not yet recruiting --> Withdrawn N=200 --> 0
- | Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed: Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol (clinicaltrials.gov) - Jan 30, 2013
P2, N=16, Active, not recruiting, Sponsor: UCB, Inc.
N=200 --> 0 Enrolling by invitation --> Active, not recruiting
- ||| Bravelle (urofollitropin) / Ferring
Enrollment open: Study of the Cleavage of the Egg in Relation to the Stimulation Treatment (clinicaltrials.gov) - Jan 29, 2013
P=N/A, N=600, Recruiting, Sponsor: Ferring Pharmaceuticals
Enrolling by invitation --> Active, not recruiting Not yet recruiting --> Recruiting
- Cimzia (certolizumab pegol) / Astellas, UCB
New P4 trial: NIMRA: Novel Imaging Markers for Rheumatoid Arthritis (clinicaltrials.gov) - Jan 21, 2013
P4, N=20, Active, not recruiting, Sponsor: University of California, San Francisco
- |||||| Firmagon (degarelix) / Astellas, Ferring
Enrollment open: One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population (clinicaltrials.gov) - Jan 15, 2013
P3, N=280, Recruiting, Sponsor: Ferring Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Cervidil (dinoprostone) / Ferring
New P2 trial: CYTOPRO: Comparison Between 25 (clinicaltrials.gov) - Jan 8, 2013
P2, N=1200, Recruiting, Sponsor: University Hospital, Toulouse
- ||| Cimzia (certolizumab pegol) / Astellas, UCB
Observational data: Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors (clinicaltrials.gov) - Jan 7, 2013
P=N/A, N=1360, Recruiting, Sponsor: UCB Pharma SA
- ||| FSH-GEX (follicle stimulating hormone) / Glycotope
Trial completion: Multiple Dose FSH-GEX(TM) in Healthy Volunteers (clinicaltrials.gov) - Jan 1, 2013
P1, N=57, Completed, Sponsor: Glycotope GmbH
Not yet recruiting --> Recruiting Recruiting --> Completed
- | Firmagon (degarelix) / Astellas, Ferring
Enrollment open: Degarelix in the Treatment of Endometriosis Recurrence (clinicaltrials.gov) - Dec 19, 2012
P3, N=100, Recruiting, Sponsor: Centre for Endocrinology and Reproductive Medicine, Italy
Recruiting --> Completed Not yet recruiting --> Recruiting
- | Firmagon (degarelix) / Astellas, Ferring
Enrollment open: Use of Degarelix in Controlled Ovarian Hyperstimulation (COH) Protocol for Women With PoliCystic Ovarian Syndrome (PCOS) (clinicaltrials.gov) - Dec 19, 2012
P3, N=80, Recruiting, Sponsor: Centre for Endocrinology and Reproductive Medicine, Italy
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| Firmagon (degarelix) / Astellas, Ferring
Enrollment open: 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy (clinicaltrials.gov) - Dec 18, 2012
P2, N=120, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Firmagon (degarelix) / Astellas, Ferring
New P2 trial: 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy (clinicaltrials.gov) - Dec 16, 2012
P2, N=120, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma, Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment open: NORD-STAR: Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose Reduction (clinicaltrials.gov) - Dec 16, 2012
P4, N=800, Recruiting, Sponsor: Karolinska Institutet
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion: CERTAIN 2: Follow-up of Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study (clinicaltrials.gov) - Dec 16, 2012
P3, N=131, Completed, Sponsor: UCB, Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion: A Comparison of Two Assessment Tools in Predicting Treatment Success of Cimzia in Rheumatoid Arthritis Subjects (clinicaltrials.gov) - Dec 13, 2012
P4, N=736, Completed, Sponsor: UCB, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed